Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomize - sprookjes - yvandenbroek - TriplyDB

Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomize

Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomize

http://www.wikidata.org/entity/Q34207990

about

Recent advances in treatment of acute coronary syndromes Biodegradable polymer Biolimus-eluting stent (Nobori®) for the treatment of coronary artery lesions: review of concept and clinical results The Ultimaster Biodegradable-Polymer Sirolimus-Eluting Stent: An Updated Review of Clinical Evidence Efficacy and safety of biodegradable polymer biolimus-eluting stents versus durable polymer drug-eluting stents: a meta-analysis Safety and efficacy of biodegradable drug-eluting vs. bare metal stents: a meta-analysis from randomized trials Preclinical study of a biodegradable polymer-based stent with abluminal sirolimus release.Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort.A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronar Dual antiplatelet therapy over 6 months increases the risk of bleeding after biodegradable polymer-coated sirolimus eluting stents implantation: insights from the CREATE study Clinical impact of routine follow-up coronary angiography after second- or third-generation drug-eluting stent insertion in clinically stable patients Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial.Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial Coronary stent thrombosis: current insights into new drug-eluting stent designs Clinical outcomes in 995 unselected real-world patients treated with an ultrathin biodegradable polymer-coated sirolimus-eluting stent: 12-month results from the FLEX Registry.Nine-month angiographic and two-year clinical follow-up of novel biodegradable-polymer arsenic trioxide-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease.Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis.Recent Advances in the Treatment of ST-Segment Elevation Myocardial Infarction.Randomized clinical trial comparing abluminal biodegradable polymer sirolimus-eluting stents with durable polymer sirolimus-eluting stents: Nine months angiographic and 5-year clinical outcomes.A bumpy and winding but right path to domestic drug-eluting coronary stents.Bleeding events and maintenance dose of prasugrel: BLESS pilot study.Histopathological Comparison among Biolimus, Zotarolimus and Everolimus-Eluting Stents in Porcine Coronary Restenosis Model.Local sustained delivery of acetylsalicylic acid via hybrid stent with biodegradable nanofibers reduces adhesion of blood cells and promotes reendothelialization of the denuded artery.Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis.Inverse Relationship between Serum VEGF Levels and Late In-Stent Restenosis of Drug-Eluting Stents.The Year in Cardiology 2012: coronary intervention.Dexamethasone-eluting vascular stents.New concepts in the design of drug-eluting coronary stents.Coronary stents: novel developments.Drug-eluting versus bare-metal coronary stents: where are we now?Meta-analysis of bioabsorbable versus durable polymer drug-eluting stents in 20,005 patients with coronary artery disease: an update.Current application and bioavailability of drug-eluting stents.Surgical versus percutaneous revascularization in patients with multivessel coronary artery disease.ST elevation myocardial infarction: recent advances and updates.The EHJ: the first years and the future.Everolimus- and sirolimus-eluting stents in patients with and without ST-segment elevation myocardial infarction.PCI and CABG surgery in 2014: CABG surgery versus PCI in CAD--surgery strikes again!The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view.Causes, assessment, and treatment of stent thrombosis--intravascular imaging insights.Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.

P2860

Q26862897-D3B169DA-9D12-4F3C-A8F3-00C92C647826 Q26864540-C62C75E4-C41C-4BF7-BDA8-DC8B26F6A7FC Q28067509-F5C044D0-6992-4666-BEAF-4012DA5DE9EB Q28534994-D7DA8979-718B-4C68-A657-6C3FB9E4557F Q28539865-1EF5DDF5-99FD-42DA-BA78-1868E22711D3 Q33733393-8EAFDBE3-3F48-4BAF-9999-09BD033AFBAF Q34002205-CFEB0628-9723-4565-986D-04906348854F Q34354151-06137AD5-0FC7-43D6-BB88-C3C36D558B6B Q34531925-C8E67DFD-CA0F-4A47-A1B6-C6A84EA61E27 Q34948151-E09CB055-2134-4352-A245-516B083B5B5B Q36060147-55ACC4A2-F742-4DB9-865F-5905D6528252 Q36384518-5A8B0046-B4DF-4AB0-AEEE-67D49E96A794 Q36514842-DEE0391E-65CD-4A1B-95AA-68453843AEE5 Q36602870-81BEBEBF-F4E5-474D-A543-87A3C112CB2C Q36804772-7D7E7A6A-F4C5-4620-B77B-D793C1A5B16E Q36954581-49C37091-B4A9-4CA3-ABEC-F7BB87F7A8DA Q37284036-A1E7F36C-1BFA-487C-81EF-630646706E67 Q37288480-BEE757EE-6BDA-43C1-B52B-21F01428ACD5 Q37300570-7D5402F5-962F-4A95-81A9-E70643A9FCE8 Q37316783-D106A97A-B3F6-4546-8BE9-8551BD0E7401 Q37390051-5264A0EC-2B0C-40A3-A47C-3CB8826EE411 Q37399625-72B2450E-58FB-4BF0-90BA-DFB5BC3702F0 Q37464405-39467089-216D-4836-9324-4CCD46146E24 Q37502920-E4942277-4488-4681-AE86-DF6DBB58D334 Q37714688-C25AB9DD-B251-4C83-96BB-E7CC5815406B Q38071284-85A2E989-1921-44DA-A98E-41D07EA636F6 Q38078557-355C3467-9DA4-4163-AF42-29E92452F137 Q38082647-50037DD6-FA15-4A5C-81B9-18AC22103679 Q38134375-09B15A0F-4914-4BB6-A771-88B01980B571 Q38162864-B3600023-79BC-4648-BBDE-49AF5C476370 Q38183346-4ED67F58-6D17-45F6-BE58-AAB5071E08CC Q38188578-338C3FBB-D09D-43F5-A81D-D1057346BB27 Q38262668-43465C92-94FB-43CE-9F43-C28C1AFC1112 Q38263602-833B8116-677F-4BF7-BEAD-E6708FBFA832 Q38270448-76B01D57-DED7-4DBC-A498-0E72D906194A Q38280156-3A0E8C25-8B3B-4B29-8485-46D4A5141A49 Q38307962-91BB0F4B-5714-4CDC-907A-00DF4232137C Q38310049-FCCBB2D2-BB08-42F2-B61E-9576B2EDDFCB Q38381419-7EC6BDA3-894A-496E-BA3D-74598D41760C Q38398230-42146172-084A-4316-8384-AB32AB019ABB

P2860

Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomize

http://www.wikidata.org/entity/Q34207990

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Biodegradable polymer drug-elu ...... -TEST 4, and LEADERS randomize

@ast

Biodegradable polymer drug-elu ...... -TEST 4, and LEADERS randomize

@en

Biodegradable polymer drug-elu ...... -TEST 4, and LEADERS randomize

@nl

type

label

Biodegradable polymer drug-elu ...... -TEST 4, and LEADERS randomize

@ast

Biodegradable polymer drug-elu ...... -TEST 4, and LEADERS randomize

@en

Biodegradable polymer drug-elu ...... -TEST 4, and LEADERS randomize

@nl

prefLabel

Biodegradable polymer drug-elu ...... -TEST 4, and LEADERS randomize

@ast

Biodegradable polymer drug-elu ...... -TEST 4, and LEADERS randomize

@en

Biodegradable polymer drug-elu ...... -TEST 4, and LEADERS randomize

@nl

P1433

Q34207990-6D79D9F0-B949-4981-8880-801973902FAF

P1476

Q34207990-D73072AF-C8BD-4131-8410-AE52175931AA

P2093

Q34207990-6C7F0032-E430-4155-AB42-5C97D4562014

Q34207990-B51A9FAE-461D-4B08-94CD-1972C9C31847

Q34207990-DC0DC41A-E30C-46A2-8BB6-C27CB4958857

Q34207990-DFC0776F-DD28-4493-8671-848D6294BD20

Q34207990-F92EC9FF-F4E8-4F77-BE4F-1CF508BE8744

P2860

Q34207990-1302ECEB-E7F5-4678-8A5C-FD09755C012B

Q34207990-156C45C5-415C-45C5-A085-063E60C15304

Q34207990-26A6A041-2AEC-44B3-BB3F-D76454D8CAC8

Q34207990-33C71B12-F4C3-43F4-8EE5-7A8BFD7D8CFF

Q34207990-372A07F5-AE1A-4614-8672-0FF1DC808096

Q34207990-3732E5F1-5791-4795-A4BA-DD107EA87A86

Q34207990-66FC4851-6274-4C74-A5C4-0FE31B9198AF

Q34207990-6C352568-976D-419F-B2AC-27FF4094D1B6

Q34207990-6E0FA316-E5EE-4C14-8CAA-6FE9314DA4EA

Q34207990-720980A4-A353-4D6D-BD72-CE9AF5E89851

P304

Q34207990-1BAE5408-F5D2-4210-83ED-03FC3DE934A4

P31

Q34207990-38486D92-E402-437C-97A5-9C46847DC7C5

Q34207990-6b01e37b-7e25-4e53-8161-ee37afeea53f

P356

Q34207990-6A50FD1C-DCDF-46A7-83B3-145A86F6D08C

P433

Q34207990-12CFF15D-053C-4DFB-B352-D7BB20C5AD47

P478

Q34207990-863755ED-768E-465C-9A8A-3C698EF4B8FC

P50

Q34207990-38E43F25-7F9D-4C38-9A82-6222F4707B80

Q34207990-511D4295-C241-414B-B5C2-296955E42DFC

Q34207990-7607E0DE-2797-4993-A367-ECB2D76AAF7C

Q34207990-C6675C43-269B-4BFE-A70C-D945C5E3D6C4

Q34207990-E1AC5F7B-8F4A-4C28-9FD4-E2AFB069C921

P577

Q34207990-255DD723-5391-418E-A539-C1FF3E93592A

P5875

Q34207990-DEF953F1-6B53-435A-B6AE-7CD74D5DA970

P698

Q34207990-9EFA118D-89F9-494E-A117-F3E6C97D2A24

P921

Q34207990-09B2D21A-0A6F-49B0-BA26-6598F73F6FB5

Q34207990-DD4FA8D2-1588-455F-B03B-DA190B38209C

Q34207990-F035C14F-46A2-4357-BCC1-590C12DE3380

P356

P1433

European Heart Journal

P1476

Biodegradable polymer drug-elu ...... -TEST 4, and LEADERS randomize

@en

P2093

Antoinette de Waha

http://www.w3.org/2001/XMLSchema#string

Bernhard Meier

http://www.w3.org/2001/XMLSchema#string

Giulio G Stefanini

http://www.w3.org/2001/XMLSchema#string

Robert A Byrne

http://www.w3.org/2001/XMLSchema#string

Steffen Massberg

http://www.w3.org/2001/XMLSchema#string

P2860

Measuring inconsistency in meta-analyses

Meta-analysis in clinical trials

Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?

Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis

A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents

Outcomes and complications associated with off-label and untested use of drug-eluting stents

Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents

Vascular responses to drug eluting stents: importance of delayed healing

Clinical end points in coronary stent trials: a case for standardized definitions.

Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis.

P304

1214-1222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHS086

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Albert Schömig

Patrick W Serruys

Stephan Windecker

P577

2012-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221976499

http://www.w3.org/2001/XMLSchema#string

P698

22447805

http://www.w3.org/2001/XMLSchema#string

P921